Oragenics Inc OGEN
We take great care to ensure that the data presented and summarized in this overview for ORAGENICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OGEN
View allLatest Institutional Activity in OGEN
Top Purchases
Top Sells
About OGEN
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Insider Transactions at OGEN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 30
2023
|
Fred Telling Director |
SELL
Open market or private sale
|
Direct |
3,500
-8.36%
|
$10,500
$3.57 P/Share
|
|
Aug 08
2023
|
Fred Telling Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+37.4%
|
-
|
|
Aug 08
2023
|
Janet Huffman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Aug 08
2023
|
Alan W Dunton Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+49.32%
|
-
|
|
Aug 08
2023
|
Kimberly M Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Aug 08
2023
|
Charles L Pope Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+49.53%
|
-
|
|
Aug 08
2023
|
Robert C Koski Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+49.32%
|
-
|
|
Dec 30
2022
|
Robert C Koski Director |
SELL
Open market or private sale
|
Indirect |
42,357
-3.7%
|
$0
$0.11 P/Share
|
|
Dec 29
2022
|
Robert C Koski Director |
SELL
Open market or private sale
|
Direct |
36,648
-17.22%
|
$0
$0.11 P/Share
|
|
Dec 15
2022
|
Robert C Koski Director |
SELL
Open market or private sale
|
Indirect |
140,497
-10.93%
|
$0
$0.18 P/Share
|
|
Dec 14
2022
|
Robert C Koski Director |
SELL
Open market or private sale
|
Indirect |
29,503
-1.13%
|
$0
$0.18 P/Share
|
|
Dec 09
2022
|
Robert C Koski Director |
SELL
Open market or private sale
|
Indirect |
48,795
-3.58%
|
$0
$0.2 P/Share
|
|
Dec 08
2022
|
Robert C Koski Director |
SELL
Open market or private sale
|
Indirect |
13,036
-0.95%
|
$0
$0.2 P/Share
|
|
Nov 30
2022
|
Robert C Koski Director |
SELL
Open market or private sale
|
Indirect |
200,000
-12.69%
|
$0
$0.19 P/Share
|
|
Nov 29
2022
|
Robert C Koski Director |
SELL
Open market or private sale
|
Indirect |
200,000
-11.26%
|
$0
$0.19 P/Share
|
|
Jun 17
2022
|
Fred Telling Director |
BUY
Open market or private purchase
|
Direct |
10,084
+0.99%
|
$0
$0.29 P/Share
|
|
May 24
2022
|
Fred Telling Director |
BUY
Open market or private purchase
|
Direct |
78,673
+7.29%
|
$0
$0.29 P/Share
|
|
May 23
2022
|
Fred Telling Director |
BUY
Open market or private purchase
|
Direct |
3,500
+0.38%
|
$0
$0.29 P/Share
|
|
May 20
2022
|
Fred Telling Director |
BUY
Open market or private purchase
|
Direct |
65,718
+6.68%
|
$0
$0.28 P/Share
|
|
May 19
2022
|
Fred Telling Director |
BUY
Open market or private purchase
|
Direct |
56,806
+6.25%
|
$0
$0.28 P/Share
|
Last 12 Months Summary
| Open market or private sale | 3.5K shares |
|---|